Daiichi Sankyo Launches New Generic Drugs Through its Daiichi Sankyo Espha Subsidiary

Tokyo, Japan (December 10, 2015) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that its generics subsidiary, Daiichi Sankyo Espha, is launching fourteen new generic drugs with six new active ingredients on Friday, December 11, as well as two new generic drugs with one new active ingredient in March 2016.

Overview
1. Product names/therapeutic categories

<table>
<thead>
<tr>
<th>Product name</th>
<th>Therapeutic category</th>
<th>Original brand name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sertraline Tablets 25mg “DSEP”</td>
<td>Selective serotonin re-uptake inhibitor</td>
<td>JZOLOFT® Tablets 25mg, 50mg</td>
</tr>
<tr>
<td>Sertraline Tablets 50mg “DSEP”</td>
<td>Selective AT1 receptor blocker/prolonged Ca antagonist combination</td>
<td>EXFORGE® Combination Tablets</td>
</tr>
<tr>
<td>AMVALO® Combination Tablets “DSEP”</td>
<td>Selective AT1 receptor blocker/prolonged Ca antagonist combination</td>
<td>EXFORGE® Combination Tablets</td>
</tr>
<tr>
<td>AMALUET® Combination Tablets 1Ban “DSEP”</td>
<td>Prolonged Ca antagonist/HMG-CoA reductase inhibitor</td>
<td>Caduet® Combination Tablets 1Ban, 2Ban, 3Ban, 4Ban</td>
</tr>
<tr>
<td>AMALUET® Combination Tablets 2Ban “DSEP”</td>
<td>Prolonged Ca antagonist/HMG-CoA reductase inhibitor</td>
<td>Caduet® Combination Tablets 1Ban, 2Ban, 3Ban, 4Ban</td>
</tr>
<tr>
<td>AMALUET® Combination Tablets 3Ban “DSEP”</td>
<td>Prolonged Ca antagonist/HMG-CoA reductase inhibitor</td>
<td>Caduet® Combination Tablets 1Ban, 2Ban, 3Ban, 4Ban</td>
</tr>
<tr>
<td>AMALUET® Combination Tablets 4Ban “DSEP”</td>
<td>Prolonged Ca antagonist/HMG-CoA reductase inhibitor</td>
<td>Caduet® Combination Tablets 1Ban, 2Ban, 3Ban, 4Ban</td>
</tr>
<tr>
<td>TAZOPIPE® Combination I.V. Solution 2.25 “DSEP”</td>
<td>β-lactamase inhibitor combination Antibiotic agent</td>
<td>ZOSYN® I.V. 2.25, 4.5 ZOSYN® I.V. Bag 4.5</td>
</tr>
<tr>
<td>TAZOPIPE® Combination I.V. Solution 4.5 “DSEP”</td>
<td>β-lactamase inhibitor combination Antibiotic agent</td>
<td>ZOSYN® I.V. 2.25, 4.5 ZOSYN® I.V. Bag 4.5</td>
</tr>
<tr>
<td>TAZOPIPE® Combination Drip I.V. Bag 2.25 “DSEP”</td>
<td>β-lactamase inhibitor combination Antibiotic agent</td>
<td>ZOSYN® I.V. 2.25, 4.5 ZOSYN® I.V. Bag 4.5</td>
</tr>
<tr>
<td>TAZOPIPE® Combination Drip I.V. Bag 4.5 “DSEP”</td>
<td>β-lactamase inhibitor combination Antibiotic agent</td>
<td>ZOSYN® I.V. 2.25, 4.5 ZOSYN® I.V. Bag 4.5</td>
</tr>
<tr>
<td>Rebamipide Tablets 100mg “DSEP”</td>
<td>Treatment for gastritis/stomach ulcer</td>
<td>Mucosta® Tablets 100mg</td>
</tr>
<tr>
<td>Tamsulosin Hydrochloride OD Tablets 0.1mg “KN”</td>
<td>Treatment for urination disorder due to enlargement of prostate</td>
<td>Harnal® D Tablets 0.1mg, 0.2mg</td>
</tr>
<tr>
<td>Tamsulosin Hydrochloride OD Tablets 0.1mg “KN”</td>
<td>Treatment for urination disorder due to enlargement of prostate</td>
<td>Harnal® D Tablets 0.1mg, 0.2mg</td>
</tr>
</tbody>
</table>

*Joint launch with Kobayashi Kako
* Regarding the TAZOPIPE formulation, in addition to initial indication (septicemia, pneumonia, pyelonephritis, cystitis), it has already received approval with one change (additional indication: febrile neutropenia (adults)) on November 25, 2015.

2) Products launched in March 2016

<table>
<thead>
<tr>
<th>Product name</th>
<th>Therapeutic category</th>
<th>Original brand name</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAMSHIA® Combination LD “SANDOZ”</td>
<td>Prolonged angiotensin II receptor antagonist/prolonged Ca antagonist combination</td>
<td>UNISIA® Combination Tablets LD, HD</td>
</tr>
<tr>
<td>CAMSHIA® Combination HD “SANDOZ” *Joint launch with Sandoz</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2. Product attributes – Daiichi Sankyo Espha measures

Daiichi Sankyo Espha has continued to maintain a level of quality based on the quality management standards of the Daiichi Sankyo Group. Thanks to initiatives such as the world’s first double-sided laser printing on tablets, Daiichi Sankyo Espha has contributed to innovations in formulations and labeling to make drugs easier to ingest and harder for patients to mistakenly take. These kinds of high value-added generic drugs are proposed as “premium generics.”

Innovation of PTP sheets and tablets

In order to prevent mistaken taking and ingestion, innovations in formulations and labeling are continuing to be developed.

- Easily recognizable original symbols

PTP sheets feature original symbol marks based on characteristics of formulations and diseases.

Example of AMVALO® Combination Tablets “DSEP” original symbol mark

- GS1 data barcode for each PTP sheet and packaging (outer box):

With the aim of helping to ensure no mistaken taking of tablets, GS1 data barcodes are printed on the back of PTP sheets. Also, for the GS1 data barcodes on the packaging (outer box), in addition to fixed information (product name, dosage, etc.), varying information (manufacture lot No., efficacy period, etc.) can also be checked.

GS1 data barcode: GS1 data barcode is a next generation barcode which has been in use as a global standard since 2010. It has the merit of enabling management of product attributes such as manufacture lot and efficacy period.
- Pitch control: Clear identification by printing of product names, active ingredients, etc. in fixed positions on each tablet of the PTP sheets.

- Double-sided printing (Sertraline Tablets, AMVALO Combination Tablets, AMALUET Combination Tablets, Tamsulosin Hydrochloride OD Tablets, CAMSHIA Combination Tablets):

  Printing of product name etc. on both sides of tablets to make them easier to distinguish.

```
Sertraline Tablets 50mg “DSEP”
```

```
AMVALO® Tablets “DSEP”
```

```
AMALUET® Combination Tablets 1,2,3,4Ban “DSEP”
```

```
Tamsulosin Hydrochloride OD Tablets 0.1mg “KN”
```

```
CAMSHIA® Combination HD “SANDOZ”
```

* Same design both sides

Other formulation and packaging innovations

- The TAZOPIPE® Combination Drip I.V. Bag, holds a volume of solution (2.25 standard) that is not available in previous products and suitable for use on child patients who weight less, with waste reduction in mind.

```
TAZOPIPE® Combination Drip I.V. Bag 2.25 DSEP
```

```
TAZOPIPE® Combination I.V. Solution 4.5 “DSEP”
```

**About Daiichi Sankyo Espha**
Daiichi Sankyo Espha is a company that manufactures and markets generic drugs, accommodating rising demand based on the spirit of Daiichi Sankyo Group corporate philosophy* of supplying pharmaceuticals to address diverse medical needs. Daiichi Sankyo Espha strives to provide peace of mind for users by fulfilling the most important pharmaceutical criteria of quality, information, and stable supply while delivering the economic benefits of generics.

*Daiichi Sankyo Group corporate philosophy: To contribute to the enrichment of life around the world through the creation of innovative pharmaceuticals, and through the provision of pharmaceuticals addressing diverse medical needs.

**Daiichi Sankyo Espha Company Overview**
Company name: Daiichi Sankyo Espha Co., Ltd.
Established: April 1, 2010
Business: Manufacture and sale of pharmaceuticals
Capital: 450 million yen
Representative: President Hiroto Yoshikawa
Headquarters: 3-5-1, Nihonbashi, Honcho, Chuo-ku, Tokyo